Personalized Management of Type 2 Diabetes Using AI-Guided (GenAIS TM) Dietary Supplementation

Personalized Management of Type 2 Diabetes Using AI-Guided (GenAIS TM) Dietary Supplementation: A Randomized Controlled Clinical Trial

This randomized controlled trial investigates the effectiveness of AI-guided dietary supplement prescriptions compared to standard physician-guided prescriptions in managing Type 2 diabetes (T2D). The study includes 160 participants with T2D, aged 40-75, who will be randomly assigned to either the control group (standard physician-guided prescriptions) or the AI-guided group (prescriptions determined by GenAIS, an AI system by Triangel Scientific). The primary objective is to compare the reduction in HbA1c levels between the two groups over 6 months. Secondary outcomes include changes in fasting glucose, lipid profiles, body weight, BMI, hsCRP levels, and adherence to the dietary supplement regimen. The AI system integrates genetic, metabolic, and clinical data to provide personalized supplement recommendations, aiming to improve glycemic control and overall metabolic health.

Inclusion Criteria:

• Age between 40 and 75 years.
• Diagnosed with Type 2 diabetes (HbA1c between 7.0% and 10.0%).
• Stable anti-diabetic medication regimen for at least 3 months prior to the study.
• Willingness to provide genetic and metabolic data.

Exclusion Criteria:

• Type 1 diabetes or other specific types of diabetes.
• Significant renal, hepatic, or cardiovascular diseases.
• Use of dietary supplements that affect glucose metabolism within the last 3 months.
• Pregnancy or breastfeeding